Paget-Schroetter综合征的管理:系统综述与Meta分析
该系统综述与Meta分析检索1990年1月至2021年12月Cochrane、PubMed和Embase数据库,纳入60篇报告共2653例患者,评估Paget-Schroetter综合征不同管理策略的临床结局。非比较分析中,仅抗凝组无症�状患者比例为0.54,导管导向溶栓联合抗凝为0.71,抗凝联合第一肋切除为0.80,导管导向溶栓联合第一肋切除为0.96;比较性报告汇总分析证实导管导向溶栓联合第一肋切除优于其他策略,但证据确定性极低。
要点
- 仅抗凝治疗Paget-Schroetter综合征,46%患者随访结束时仍有持续症状。
- 导管导向溶栓联合第一肋切除组96%患者随访结束时无症状。
- 比较性报告汇总分析证实导管导向溶栓联合第一肋切除优于抗凝、抗凝联合第一肋切除及导管导向溶栓联合抗凝,但证据确定性极低。
核心结论
- 仅抗凝的非手术治疗Paget-Schroetter综合征导致46%患者持续症状,而导管导向溶栓联合第一肋切除组96%患者随访结束时无症状。
- Meta分析证实导管导向溶栓联合第一肋切除优于抗凝、导管导向溶栓联合抗凝及抗凝联合第一肋切除。
- 纳入报告的总体质量为中等,证据确定性极低。
研究设计与样本
- 遵循PRISMA 2020指南开展的系统综述与Meta分析,检索Cochrane、PubMed和Embase数据库1990年1月至2021年12月发表的报告。
- 共纳入60篇报告,合计2653例患者,总体质量为中等。
- 主要终点为末次随访时无症状患者比例,次要终点为初始治疗成功、血栓复发或持续闭塞及末次随访时通畅率。
- 采用GRADE方法评估证据质量。
主要发现
- 非比较分析中无症状患者比例:抗凝组0.54,导管导向溶栓联合抗凝组0.71,抗凝联合第一肋切除组0.80,导管导向溶栓联合第一肋切除组0.96。
- 比较性报告汇总分析证实导管导向溶栓联合第一肋切除优于抗凝(OR 13.89,95%CI 1.08-179.04;p=.040,I²=87%,证据确定性极低)。
- 导管导向溶栓联合第一肋切除优于抗凝联合第一肋切除(OR 2.29,95%CI 1.21-4.35;p=.010,I²=0%,证据确定性极低)。
- 导管导向溶栓联合第一肋切除优于导管导向溶栓联合抗凝(OR 8.44,95%CI 1.12-59.53;p=.030,I²=63%,证据确定性极低)。
- 次要终点结果支持导管导向溶栓联合第一肋切除。
临床怎么用
- 原文结论指出,仅抗凝的非手术治疗Paget-Schroetter综合征导致46%患者持续症状,而导管导向溶栓联合第一肋切除组96%患者随访结束时无症状。
- 原文结论指出,Meta分析证实导管导向溶栓联合第一肋切除优于抗凝、导管导向溶栓联合抗凝及抗凝联合第一肋切除。
局限性
- 纳入报告的总体质量为中等,证据确定性极低。
- 导管导向溶栓联合第一肋切除与抗凝比较的汇总分析异质性I²=87%。
- 导管导向溶栓联合第一肋切除与导管导向溶栓联合抗凝比较的汇总分析异质性I²=63%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Currently, there is no consensus on the optimal management of Paget-Schroetter syndrome (PSS). The objective was to summarise the current evidence for management of PSS with explicit attention to the clinical outcomes of different management strategies. DATA SOURCES: The Cochrane, PubMed, and Embase databases were searched for reports published between January 1990 and December 2021. REVIEW METHODS: A systematic review and meta-analysis was conducted following PRISMA 2020 guidelines. The primary endpoint was the proportion of symptom free patients at last follow up. Secondary outcomes were success of initial treatment, recurrence of thrombosis or persistent occlusion, and patency at last follow up. Meta-analyses of the primary endpoint were performed for non-comparative and comparative reports. The quality of evidence was assessed using the GRADE approach. RESULTS: Sixty reports were included (2 653 patients), with overall moderate quality. The proportions of symptom free patients in non-comparative analysis were: anticoagulation (AC), 0.54; catheter directed thrombolysis (CDT) + AC, 0.71; AC + first rib resection (FRR), 0.80; and CDT + FRR, 0.96. Pooled analysis of comparative reports confirmed the superiority of CDT + FRR compared with AC (OR 13.89, 95% CI 1.08 - 179.04; p = .040, I2 87%, very low certainty of evidence), AC + FRR (OR 2.29, 95% CI 1.21 - 4.35; p = .010, I2 0%, very low certainty of evidence), and CDT + AC (OR 8.44, 95% CI 1.12 - 59.53; p = .030, I2 63%, very low certainty of evidence). Secondary endpoints were in favour of CDT + FRR. CONCLUSION: Non-operative management of PSS with AC alone results in persistent symptoms in 46% of patients, while 96% of patients managed with CDT + FFR were symptom free at end of follow up. Superiority of CDT + FRR compared with AC, CDT + AC, and AC + FRR was confirmed by meta-analysis. The overall quality of included reports was moderate, and the level of certainty was very low.
引用
- Hoexum F, Hoebink M, Coveliers HME, et al. Management of Paget-Schroetter Syndrome: a Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2023. PMID: 37678659. doi:10.1016/j.ejvs.2023.08.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。